(Circulation. 1998;98:2235-2240.)
© 1998 American Heart Association, Inc.
Clinical Investigation and Reports |
Hemodynamic and Coronary Effects of the Endothelin Antagonist Bosentan in Patients With Coronary Artery Disease
From Cardiology (M.F., U.K., B.M.), Cardiovascular Research (R.R.W., G.N.) and Hypertension Division (S.S.), University Hospital, Bern; Cardiology (G.N., T.F.L.), University Hospital Zürich; and F. Hoffmann–La Roche, Basel (R.S., C.R.J., M.C.), Switzerland.
Correspondence to Thomas F. Lüscher, MD, FESC, Professor and Head of Cardiology, University Hospital, CH-8091 Zürich, Switzerland.
Background—Endothelin is a potent endothelium-derived vasoconstrictor peptide with proliferative properties. Elevated levels of the peptide occur in coronary artery disease; however, its pathophysiological role as a regulator of coronary tone and structure is uncertain. Endothelin-receptor antagonists are specific tools to clarify this issue and might be useful in the treatment of coronary artery disease.
Methods and Results—In a double-blind, placebo-controlled randomized study, we investigated the effects of the ETA/ETB endothelin-receptor antagonist bosentan or placebo on systemic and coronary hemodynamics in 28 patients with angiographically documented stable coronary artery disease by quantitative coronary angiography and an intracoronary Doppler guidewire. Bosentan 200 mg IV decreased systolic blood pressure (P<0.05), whereas heart rate increased slightly (P<0.05). Coronary diameter increased, particularly in vessels with no or mild angiographic changes (P<0.01). Glycerol trinitrate did not further dilate these segments, whereas coronary diameter increased significantly after nitrate in the placebo group. The increase in coronary diameter after bosentan correlated inversely with plasma LDL-cholesterol levels (P<0.01) in both stenotic and angiographically normal coronary segments. Coronary flow velocity did not change. Bosentan was well tolerated.
Conclusions—Endogenous endothelin exerts a vasoconstrictor tone in epicardial coronary arteries of patients with coronary artery disease, as evidenced by the vasodilation exerted by the combined ETA/ETB endothelin-receptor antagonist bosentan under acute conditions. Bosentan can safely be given to these patients. Hence, further long-term studies are necessary to determine the therapeutic potential of endothelin-receptor antagonists in patients with coronary artery disease.
Key Words: endothelin • bosentan • blood flow • coronary disease • angiography
This article has been cited by other articles:
 |
|
 |
|
  D. J. Duncker and R. J. Bache Regulation of Coronary Blood Flow During Exercise Physiol Rev, July 1, 2008; 88(3): 1009 - 1086. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Ikonomidis, E. J. Hilton, K. Payne, A. Harrell, L. Finklea, L. Clark, S. Reeves, R. E. Stroud, A. Leonardi, F. A. Crawford Jr, et al. Selective Endothelin-A Receptor Inhibition After Cardiac Surgery: A Safety and Feasibility Study Ann. Thorac. Surg., June 1, 2007; 83(6): 2153 - 2161. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P.J. Halcox, K. R.A. Nour, G. Zalos, and A. A. Quyyumi Endogenous Endothelin in Human Coronary Vascular Function: Differential Contribution of Endothelin Receptor Types A and B Hypertension, May 1, 2007; 49(5): 1134 - 1141. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E Pyke and M. E Tschakovsky The relationship between shear stress and flow-mediated dilatation: implications for the assessment of endothelial function J. Physiol., October 15, 2005; 568(2): 357 - 369. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ergul, J. S. Johansen, C. Stromhaug, A. K. Harris, J. Hutchinson, A. Tawfik, A. Rahimi, E. Rhim, B. Wells, R. W. Caldwell, et al. Vascular Dysfunction of Venous Bypass Conduits Is Mediated by Reactive Oxygen Species in Diabetes: Role of Endothelin-1 J. Pharmacol. Exp. Ther., April 1, 2005; 313(1): 70 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Rich and V. V. McLaughlin Endothelin Receptor Blockers in Cardiovascular Disease Circulation, November 4, 2003; 108(18): 2184 - 2190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. W Kenyon and J. M Nappi Bosentan for the Treatment of Pulmonary Arterial Hypertension Ann. Pharmacother., July 1, 2003; 37(7): 1055 - 1062. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Gottlieb The neurohormonal paradigm:have we gone too far? J. Am. Coll. Cardiol., May 7, 2003; 41(9): 1458 - 1459. [Full Text] [PDF]
|
|
|
|
 |
|
 P.J. Cowburn and J.G.F. Cleland Endothelin antagonists for chronic heart failure: do they have a role? Eur. Heart J., October 1, 2001; 22(19): 1772 - 1784. [PDF]
|
|
|
|
|
|
C. Ihling, T. Szombathy, B. Bohrmann, M. Brockhaus, H. E. Schaefer, and B. M. Loeffler Coexpression of Endothelin-Converting Enzyme-1 and Endothelin-1 in Different Stages of Human Atherosclerosis Circulation, August 21, 2001; 104(8): 864 - 869. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. R. Bond, B. H. Dorman, M. J. Clair, C. A. Walker, M. L. Pinosky, S. T. Reeves, S. Walton, J. M. Kratz, J. L. Zellner, A. J. Crumbley III, et al. Endothelin-1 during and after cardiopulmonary bypass: Association to graft sensitivity and postoperative recovery J. Thorac. Cardiovasc. Surg., August 1, 2001; 122(2): 358 - 364. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. E. Spieker, G. Noll, F. T. Ruschitzka, and T. F. Luscher Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future? J. Am. Coll. Cardiol., May 1, 2001; 37(6): 1493 - 1505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. MacCarthy, N. C. Pegge, B. D. Prendergast, A. M. Shah, and P. H. Groves The physiological role of endogenous endothelin in the regulation of human coronary vasomotor tone J. Am. Coll. Cardiol., January 1, 2001; 37(1): 137 - 143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. F. Luscher and M. Barton Endothelins and Endothelin Receptor Antagonists : Therapeutic Considerations for a Novel Class of Cardiovascular Drugs Circulation, November 7, 2000; 102(19): 2434 - 2440. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. S. Kyriakides, D. Th. Kremastinos, T. M. Kolettis, A. Tasouli, A. Antoniadis, and D. J. Webb Acute Endothelin-A Receptor Antagonism Prevents Normal Reduction of Myocardial Ischemia on Repeated Balloon Inflations During Angioplasty Circulation, October 17, 2000; 102(16): 1937 - 1943. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z S Kyriakides, D T Kremastinos, E Bofilis, D Tousoulis, A Antoniadis, and D J Webb Endogenous endothelin maintains coronary artery tone by endothelin type A receptor stimulation in patients undergoing coronary arteriography Heart, August 1, 2000; 84(2): 176 - 182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. E. Spieker, V. Mitrovic, G. Noll, R. Pacher, M. R. Schulze, J.o. Muntwyler, C. Schalcher, W. Kiowski, T. F. Luscher, and on behalf of the ET 003 Investigators Acute hemodynamic and neurohumoral effects of selective ETA receptor blockade in patients with congestive heart failure J. Am. Coll. Cardiol., June 1, 2000; 35(7): 1745 - 1752. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P.J. Halcox, K. R.A. Nour, G. Zalos, and A. A. Quyyumi Coronary Vasodilation and Improvement in Endothelial Dysfunction With Endothelin ETA Receptor Blockade Circ. Res., November 23, 2001; 89(11): 969 - 976. [Abstract] [Full Text] [PDF]
|
|